Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
CNMD Transcript
CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call presents a mixed picture: improved profitability, positive revenue growth guidance, and margin improvements are balanced by concerns over increased interest expenses and supply chain issues. The Q&A section reveals management's vague responses on key metrics, which could create uncertainty. The company's market cap suggests moderate price sensitivity. Overall, despite some positive aspects, the lack of clarity on critical issues and potential financial headwinds lead to a neutral prediction, with stock price expected to remain stable within a -2% to 2% range over the next two weeks.
CONMED Corporation (CNMD) Q4 2025 Earnings Call Transcript
Positive1-28
The earnings call highlights strong financial performance with EPS growth and improved cash flow. The transition to a share repurchase program and strategic focus on high-margin platforms are positive indicators. The Q&A reveals confidence in growth opportunities and strategic focus, despite minor portfolio adjustments. The positive sentiment is reinforced by strong OUS growth and a balanced approach to M&A and R&D investments. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
CONMED Corporation (CNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
CONMED Corporation (CNMD) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed picture: while there is a slight increase in EPS and cash flow, there are concerns about declining gross margins, a significant drop in GAAP net income, and management's reluctance to provide future guidance. The leverage ratio improvement and AirSeal's growth are positives, but the orthopedic backlog and tariff impacts are negatives. The market cap suggests moderate volatility, leading to a neutral stock price prediction.
CNMD Slides
CNMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
